Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Claris Ventures SGR is a venture capital firm established in 2019 and headquartered in Torino, Italy. The firm specializes in early-stage investments, particularly in biopharma companies that have emerged from the Italian research and development ecosystem. Claris Ventures aims to support innovation in the pharmaceutical sector by investing in companies that are developing transformational drugs to address significant unmet clinical needs.
As of now, Claris Ventures manages multiple specialized venture capital funds, including Claris Biotech I and Claris Biotech II. These funds focus on seed and Series A investments, emphasizing the importance of early-stage biotech innovations. The firm has built a portfolio of 11 companies, showcasing its commitment to fostering growth in the biopharma sector.
Claris Ventures has established a reputation for providing not only capital but also expertise and hands-on support to its portfolio companies. This approach facilitates clinical development programs and enhances value creation based on clinical evidence.
Claris Ventures specializes in equity investments in early-stage biopharma companies, with a strong emphasis on therapeutic areas such as oncology, immunology, and rare diseases. The firm typically invests in seed and Series A stages, providing capital ranging from €500,000 to €3 million, depending on the specific needs of the portfolio companies.
The firm seeks to partner with companies that are developing innovative solutions to address significant unmet clinical needs. Claris Ventures not only provides financial backing but also offers strategic guidance and operational support to help companies navigate the complexities of clinical development. This hands-on approach is designed to maximize the potential for success in bringing new therapies to market.
Claris Ventures is particularly interested in companies that demonstrate a strong scientific foundation and a clear path to clinical validation. The firm values founders who are deeply knowledgeable about their fields and are committed to advancing their innovations.
Claris Ventures has built a diverse portfolio of 11 companies, primarily focused on biopharma innovations. Notable portfolio companies include:
This portfolio reflects Claris Ventures' commitment to supporting innovative biopharma companies that are addressing critical healthcare challenges.
Pietro Puglisi - Managing Partner. Pietro has extensive experience in venture capital and has led numerous successful investments in the biopharma sector.
Ciro Spedaliere - Managing Partner. Ciro specializes in early-stage investments and has a strong background in pharmaceutical development.
Giulia Vestri - Partner. Giulia focuses on identifying promising biopharma startups and has a keen eye for innovative technologies.
Paolo Vigo - Investment Manager. Paolo has a background in finance and investment analysis, contributing to the firm's due diligence processes.
Gianmarco Pallavicini - Senior Associate. Gianmarco supports portfolio companies with operational insights and strategic planning.
Giuditta Magnifico - Associate. Giuditta assists in sourcing new investment opportunities and conducting market research.
Raffaele Troya - Finance & Administration Manager. Raffaele oversees the financial operations of the firm.
Araceli Albano - Internal Accounting & Administration. Araceli manages the internal accounting processes.
Roberto De Ponti - Senior Advisor. Roberto provides strategic advice based on his extensive industry experience.
Laura Iris Ferro - Senior Advisor. Laura offers insights into market trends and investment strategies.
Manilo Marocco - Senior Advisor. Manilo specializes in regulatory affairs and compliance in the biopharma sector.
Michael Hodges - Entrepreneur in Residence. Michael supports portfolio companies with entrepreneurial guidance.
Luca Melindo - Advisor. Luca provides insights into business development and commercialization strategies.
Cristina Tumiatti - Independent Director. Cristina brings governance expertise to the firm's operations.
To pitch Claris Ventures, founders should send an email to info@clarisventures.com with a detailed pitch deck. The deck should include information about the technology, market opportunity, competitive landscape, and team qualifications.
Claris Ventures prefers to receive pitches via email rather than through online portals. Founders can expect a response within a few weeks, depending on the volume of inquiries.
A warm introduction is beneficial but not mandatory. The firm values well-prepared pitches that clearly articulate the startup's vision and potential impact.
In recent months, Claris Ventures has been active in funding innovative projects within the biopharma sector. Notably, Haptena Therapeutics secured €3 million in seed financing to develop treatments for KRAS-driven cancers, showcasing the firm's commitment to supporting emerging biopharma companies.
Additionally, Claris Ventures continues to expand its portfolio, focusing on companies that are developing groundbreaking therapies to address significant unmet clinical needs. The firm remains dedicated to fostering innovation in the pharmaceutical sector through its investments.
What are Claris Ventures' investment criteria?
Claris Ventures focuses on early-stage biopharma companies, particularly in oncology, immunology, and rare diseases. The firm looks for companies with a strong scientific foundation and a clear path to clinical validation.
How can I pitch to Claris Ventures?
Founders can reach out via email at info@clarisventures.com. A well-prepared pitch deck should include details about the technology, market opportunity, and team.
What makes Claris Ventures different from other investors?
Claris Ventures provides not only capital but also hands-on support and expertise in clinical development, which is crucial for biopharma companies navigating complex regulatory environments.
What is the typical check size for investments?
Claris Ventures typically invests between €500,000 and €3 million in seed and Series A rounds, depending on the specific needs of the company.
What geographic areas does Claris Ventures focus on?
The firm primarily invests in companies based in Europe, particularly those emerging from the Italian research and development ecosystem.
What kind of post-investment involvement can founders expect?
Claris Ventures is actively involved in the development of its portfolio companies, providing operational support and strategic guidance to help them achieve their clinical and commercial goals.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.